Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Biotechnology
Analysts and crystal ball gazers in pharma love nothing more than a battle for dominance in a major market. 30 September 2019
Pharmaceutical
More than 700 drugs have disappeared from the Russian pharmaceutical market since the beginning of the current year, according to recent statements by officials of the Russian Ministry of Health and industry’s analysts, reports The Pharma Letter’s local correspondent. 30 September 2019
Biotechnology
Swiss pharma giant Roche has officially announced localization of two of its innovative drugs in Russia at the facilities of its local partners, reports The Pharma Letter’s local correspondent. 30 September 2019
Pharmaceutical
Pivotal data from a Phase II study of the FGFR inhibitor pemigatinib will be used to support a US filing later in the year, says Incyte chief executive Hervé Hoppenot. 27 September 2019
Biotechnology
In Cambridge, USA, just around the corner from fellow gene therapy specialist bluebird bio, a less well-known biotech startup could be about to shake up the market for certain rare disease therapies. 24 September 2019
Pharmaceutical
Global pharmaceutical companies hope to increase their share of public procurements in Russia as soon as this year, thanks to the new methodology on the formation of the initial maximum price for state contracts, which has been recently introduced by the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 23 September 2019
Pharmaceutical
UK pharma major GlaxoSmithKline has signed an agreement with Russian drugmaker Nanolek on the localization of vaccine production in Russia by 2021, according to recent statements of the companies, reports The Pharma Letter’s local correspondent. 23 September 2019
Pharmaceutical
Heavy rains across several parts of India have provided a shot in the arm for anti-infective drugs that have been on the decline for the past several months. The category of anti-infective drugs grew at 15.3% year-on-year in August, compared to the Indian pharmaceutical market growth of 9.4%, reports The Pharma Letter’s India correspondent. 23 September 2019
Generics
China's revised drug law is set to provide a major fillip to the Indian pharma industry. As cancer patients in China gear up to import drugs not registered with the Chinese regulators, the move is expected to be a shot in the arm for Indian oncology drug majors, reports The Pharma Letter’s local correspondent. 21 September 2019
Pharmaceutical
With the news of data manipulation in Novartis’ preclinical trials of Zolgensma (onasemnogene abeparvovec-xioi), questions have arisen around the FDA’s opinions on data accuracy and integrity. Zolgensma, a gene therapy for spinal muscular atrophy (SMA) in children, is currently the most expensive drug on the market, with a single dose costing up to $2.1million.1,2 In her exclusive column for the Pharma Letter, Dr Nicola Davies explores the measures put in place to tackle data accuracy after the fallout of the Novartis scandal. 18 September 2019
Pharmaceutical
Epidermolysis bullosa (EB) is a class of rare diseases that result in fragile skin prone to injury and blistering.1 The last week in October is EB Awareness Week – an apt time to build knowledge on this severe condition for which common subtypes are estimated to occur in 1 in every 50,000 births globally across all ethnicities and genders.1 17 September 2019
Biotechnology
While there are several commonly-cited reasons for the present pre-eminence of the Cambridge-Boston biotech cluster, it's clear that the hub is greater than the sum of its parts. 16 September 2019
Pharmaceutical
Russian drugmaker Biocad together with the Chinese firm Shanghai Pharmaceuticals Holding have confirmed their previously-announced plans to invest about $250 million in the development of their newly-established pharmaceutical joint venture in China, reports The Pharma Letter’s local correspondent. 16 September 2019
Biotechnology
US biotech major Biogen] has completed registration of Spinraza (nusinersen), one of the world’s most expensive drugs, for the treatment of spinal muscular atrophy (SMA) in Russia, according to the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 16 September 2019
Pharmaceutical
Foreign pharma firms operating in Japan face a recurring dilemma simply stated: Who should be our company president? What makes this decision different from any other country organization? Long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer, in his exclusive column for The Pharma Letter, says that, rather than hiding behind the knee jerk answer that says, “Because Japan is different,” let’s take an objective look at the issues. 16 September 2019
Pharmaceutical
The Russian government has decided to allocate additional funding for the purchases of some vital, imported drugs, which are not produced in the country, amid fears of their potential shortage in the local market, according to recent statements made by an official spokesman of the Russian Ministry of Health as well as some industry’s analysts, reports The Pharma Letter’s local correspondent. 10 September 2019
Pharmaceutical
Howard Rowe, managing director and head of healthcare, Hayfin Capital Management, considers the impact of divestments necessitated by big companies' major acquisitions, in an Expert View piece. 5 September 2019
Biotechnology
Investors in the Atlas Venture-backed immuno-oncology specialist Surface Oncology have had a rough time since the company went public in New York, early in 2018. 5 September 2019
Pharmaceutical
The UK’s Vaccines Manufacturing Innovation Centre (VMIC) is not due to open until 2022, but its first permanent chief executive has already been announced. 4 September 2019
Pharmaceutical
The Russian government has announced its plans to increase state funding for the purchases of orphan drugs and create conditions for the beginning of their production within the country, according to recent statements from the state press-service, reports The Pharma Letter’s local correspondent. 2 September 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze